P/B
0,4
Pliant Therapeutics
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
$61.9M
Market Cap • 10/8/2026
2015
(11 years)
Founded
2020
(6 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
2,4
EPS
—
Market Cap
Market Cap
61,9M
EV
-67,4M
EV/Revenue
0
EV/EBITDA
0,7
EV/EBIT
0,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,2%
Total Yield
-0,2%
Payout
0%
Retained Earnings
-901,8M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
13%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-100%
CAGR Op. Income 5Y
3,6%
CAGR Net Income 5Y
2,6%
CAGR EPS 5Y
-8,2%
CAGR OCF 5Y
1,6%
Leverage
N.D./EBITDA
1,3
Debt/Equity
0%
Current Ratio
9,9
Quick Ratio
9,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!